Compare IDEXX Laboratories, Inc. (IDXX) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs AT&T Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $571.77 (market cap $46.22B), while AT&T Inc. trades at $24.14 (market cap $167.88B). The key difference: AT&T Inc. is far larger — about 3.6× IDEXX Laboratories, Inc.'s market cap, and AT&T Inc. pays a 4.53% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | T | |
|---|---|---|
Market Cap | $46.22B | $167.88B |
Sector | Health | Media |
52-Week High | $766.68 | $29.62 |
52-Week Low | $526.44 | $20.49 |
Enterprise Value | $47.12B | $313.20B |
Dividend Yield | — | 4.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
AT&T (T) trades at $24.19, up 0.46% today, with a bullish technical signal from moving averages but overbought short-term RSI. The company shows strong fundamentals with a P/E of 8.09, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights its focus on fiber expansion and AI integration, while cash flow improved to $15.12B net in 2025.
Outlook is positive with a consensus price target of $27.69, offering 14.5% upside, supported by a 4.8% dividend yield. Risks include competitive pressure from SpaceX's Starlink and high debt levels. Analysts are mixed but lean bullish, with 41% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
